Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1301-1320 of 2,120 trials

Urethral Stenosis: Innovative Fat Injection Treatment

We are studying the safety and potential benefits of injecting fat-derived cells for men with recurrent urethral stenosis after surgery. This trial aims to see if this treatment can improve symptoms and reduce the need for further procedures.

Urethral Stenosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesUrology

Early-Stage Colon Cancer: NICHE Trial for Immunotherapy

We are studying a new immunotherapy treatment for patients with early-stage colon cancer to see if it can reduce tumors before surgery. The trial also aims to identify biomarkers that may help tailor treatments and improve patient outcomes.

Colon or Rectosigmoid Adenocarcinoma≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Ventilator-Associated Pneumonia: Antimicrobial Stewardship Study

We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.

Ventilator Associated PneumoniaIntensive Care>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Skin Cancer Treatment: The BLESS Trial

We are investigating whether reducing the dose of bleomycin in electrochemotherapy can still effectively treat skin cancers. This study aims to see if patients can benefit from less medication while achieving similar tumor response.

Skin Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

Behçet’s Disease Uveitis: Adalimumab vs. Tocilizumab

We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.

Severe Uveitis of Behçet’s Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOphthalmologyRheumatology

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Colorectal Cancer: PIPAC Treatment Study

We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Dupilumab for Uncontrolled Moderate to Severe Asthma

We are studying whether dupilumab can help prevent lung function decline in adults with uncontrolled moderate to severe asthma. This trial will compare its effects to a placebo over time.

AsthmaMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementAllergologyPulmonology

Omalizumab Withdrawal in Severe Allergic Asthma

We are studying whether stopping Omalizumab after long-term treatment is as effective as continuing it for patients with well-controlled severe allergic asthma. This trial aims to assess asthma control and quality of life over time.

Allergic Asthma1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

NK Cell Infusion for Sarcoma in Young Patients

We are testing a new immunotherapy using activated NK cells for children, adolescents, and young adults with refractory sarcomas. The goal is to evaluate its safety and effects after chemotherapy or radiotherapy.

Sarcomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Oxytocin Treatment for Autism in Children

We are studying whether multiple doses of oxytocin can improve social symptoms in children with autism and intellectual disability. The trial also looks at other behavioral changes and stress-related measurements.

Autism Spectrum Disorder6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPsychiatry

Cancer Treatments: Impact on Speech and Quality of Life

We are studying how different cancer treatments affect speech understanding in noise and overall quality of life for patients. This research may help us understand the cognitive effects of these treatments over time.

Bladder CancerTesticular SeminomaHead and Neck Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesOncologyPsychiatry

CSL889 for Sickle Cell Disease: A New Treatment

We are studying the safety and effects of CSL889 in adults and adolescents with sickle cell disease during painful vaso-occlusive crises. The goal is to see if it helps speed up recovery compared to a placebo.

Sickle Cell Anemia with Crisis≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Colon Cancer: Dostarlimab with CAPEOX

We are studying a new treatment combining dostarlimab with CAPEOX for people with untreated Stage III colon cancer. The goal is to see if this combination is more effective and safe compared to CAPEOX alone.

Metastatic Colon CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Recurrent Meningioma: [177Lu]Lu-DOTATATE Treatment Study

We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.

Meningioma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplantation: Donor Modified Immune Cells

We are studying whether using specially modified immune cells can help patients tolerate their new kidney better than standard treatments. The trial also looks at the safety of this new approach in preventing infections and other complications.

Kidney Transplant>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Multiple Sclerosis: Treatment Withdrawal Study for Older Adults

We are investigating whether stopping disease-modifying therapies is safe for people aged 55 and over with inactive relapsing-remitting multiple sclerosis. The study will help us understand its effects on relapse rates, disability, and quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Preventing C. difficile Infections: Oral Vancomycin for Stem Cell Transplant Patients

We are studying if oral vancomycin can help prevent infections in patients receiving allogeneic stem cell transplants. This research aims to see if it reduces the risk of Clostridium difficile infections during their hospital stay.

Clostridium Difficile InfectionPatients Hospitalized for Allogeneic Hematopoietic Stem Cell Transplantation≤3 monthsConfirmation phase (III)Standard MedicinesPartially RemoteHematologyInfectious Diseases